DMTweet: a psychedelic tweet recap

a PsyMed Ventures x Business Trip collab

DMTweet is a newsletter of psychedelic tweets that catch our eye 👀.

This is a collaboration between PsyMed Ventures and Business Trip (yes, we’re the folks working on both 🙃).

Tweets include: Industry updates 💼, Therapy 🛋️, Psychedelic research 🧪, Neuroscience 🧠, Consciousness ✨, Indigenous reciprocity ⚖️, Regulatory updates 📜, and Trippy ideas 👽.

Inclusion = interesting ≠ endorsements.

Let’s get to it….

Michael Haichin @MichaelHaichin

NIH Psychedelic workshop was pretty great. Suggest watching the recordings whenever they are released. Sharing some highlights below 1/

(↑ click to see thread ↑)

Yeji Jesse Lee 이예지 @jesse_yeji

Big Pharma firm Otsuka makes another investment into psychedelics. The co's McQuade Center is investing $5 million in @MindsetPharma to develop two psychedelic compounds through phase I trials Otsuka invested in @COMPASSPathway' series B round in 2020.

bloomberg.comBloomberg - Are you a robot?

@hamiltonmorris @HamiltonMorris

The DEA have announced their intention to place five tryptamine psychedelics in schedule I on February 14. Despite apparent progress, the gears of prohibition continue to grind away at personal and scientific freedom. federalregister.gov/documents/2022…

Reilly Capps @ReillyCapps

scientific paper analyzed bad trip reports. "distortions at the level of thought were the main cause for bad trips" guides say: "come back to the body, to the senses."

journals.plos.orgSelf-reported negative outcomes of psilocybin users: A quantitative textual analysisPsilocybin, a substance mainly found in mushrooms of the genus psilocybe, has been historically used for ritualistic, recreational and, more recently, medicinal purposes. The scientific literature suggests low toxicity, low risk of addiction, overdose, or other causes of injury commonly caused by su…

Olson Lab @DEOlsonLab

We have found the same thing when administering psychedelics! We recommend that experimenter sex be reported in methods sections.

BryanRoth @zenbrainest

'We found that mice manifest aversion to human male odours, preference to female odours, and increased susceptibility to stress when handled by male experimenters.' https://t.co/CyxIvpa76g

SamChapman.eth @SeriouslySamuel

Dear Psychedelic Community, Can we please replace the valuation statements of how much the “market” is going to be worth by X year, and instead highlight the number of people that stand to benefit from accessing safe and legal psychedelic services? k, thx bye

QC @QiaochuYuan

thread of therapy and therapy-like thingies that have helped me or people i know:

Dr. Emily Anhalt @dremilyanhalt

There is a whole lot of Live Laugh Love pop-psychology bullsh*t out there. Time to bust some myths 🧵👇

Jacob S. Aday, Ph.D. @JacobSAday

I feel like a biopic or even series on Timothy Leary would kill—his life story is insane

Zac Kamenetz @zackamenetz

Tell me you live in Berkeley without telling me you live in Berkeley

Jeremy Gardner @Disruptepreneur

Just received the initial green light from a group of foremost neuroscientists and researchers at a top university to develop a study and set of experiments based on a hypothesis and test I conceived of while blasted off on DMT.

Until next time…

Greg, Matias, and Dina

🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄

🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄🍄

DMTweet is a collab between PsyMed Ventures and Business Trip. PsyMed Ventures is a community-focused fund and syndicate investing in psychedelic medicine and mental health tech. Business Trip is a podcast about psychedelic entrepreneurship. Our mission is to help expand access to psychedelic medicine and mental health.

Crunchbase News @crunchbasenews

PsyMed Ventures founders tell us the new $25M fund will invest in early-stage startups, primarily those working on psychedelics, as well as startups working on neurotechnology, digital health and precision psychology to help treat mental ailments. news.crunchbase.com/news/psymed-ve…